By Daniel Park, MS, Health Content Specialist. Medically reviewed by Dr. Hassan Karimi, MD, Board-Certified Endocrinology.
Last spring, a 52-year-old named Rachel in Fort Worth texted her endocrinologist at 11 p.m. on a Tuesday. "I've gained nine pounds in six weeks," she wrote. "Is it the CombiPatch or am I losing my mind?" Her doctor, who'd started her on the estradiol/norethindrone acetate patch for menopausal symptoms two months earlier, told her the next morning: "Probably a little of both, and that's okay." Rachel's question is the same one roughly 70 people type into Google every month, and the answer is more layered than a simple yes or no.
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the GLP-1 Lifestyle & Adherence hub.
The Short Answer, Then the Longer One
CombiPatch (estradiol/norethindrone acetate transdermal system) lists weight changes among its reported side effects. In clinical trials, weight gain occurred in a small but real percentage of users, typically in the range of 2 to 5 pounds during the first several months. But here's the thing: perimenopause and menopause themselves are associated with shifts in body composition, including increased visceral fat and fluid retention, independent of any medication. Disentangling what the patch is doing from what midlife hormonal shifts are doing is genuinely hard, even for clinicians.
The progestin component (norethindrone acetate) is the more likely culprit when weight gain does occur. Progestins can increase appetite and promote fluid retention. Estradiol alone, by contrast, tends to be metabolically neutral or even slightly favorable for body composition.
So: yes, the CombiPatch can cause weight gain in some women. No, it's not inevitable. And the magnitude, when it happens, is usually modest.
Why This Question Keeps Coming Up in the GLP-1 Conversation
You'd think a question about a hormone patch wouldn't show up in a GLP-1 content hub. But the overlap is real. Many women in their late 40s and 50s start HRT for menopausal symptoms and simultaneously begin investigating GLP-1 receptor agonists for weight management. The two treatment decisions collide in the same doctor's office, sometimes in the same appointment.
GLP-1 receptor agonists work by mimicking the endogenous incretin hormone GLP-1. They slow gastric emptying, suppress glucagon release, enhance glucose-dependent insulin secretion, and act centrally on appetite-regulating circuits. For women already frustrated by HRT-related weight shifts, these medications can feel like the other half of the equation.
The connection matters because the weight gain from CombiPatch (or any combined HRT) is often the event that sends a patient looking for pharmacologic weight-loss options. Understanding what the patch is actually doing to your metabolism helps you and your prescriber decide whether adding a GLP-1 is the right next step or whether adjusting the HRT itself might be sufficient.
How the GLP-1 Market Actually Works (And Why It Matters Here)
If you've started researching GLP-1 medications, you've probably noticed the landscape is fragmented. It is not one industry. It's at least four, and they operate under different rules.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Brand manufacturers like Eli Lilly (Mounjaro, Zepbound) and Novo Nordisk (Ozempic, Wegovy, Saxenda) sell FDA-approved products with full regulatory oversight. List prices are set by the manufacturer; what you actually pay depends on insurance. Manufacturer savings programs exist but typically exclude Medicare, Medicaid, and other government-funded coverage.
Compounding pharmacies are state-licensed facilities that prepare personalized medications under a prescriber's order for a specific patient. They follow USP 795 (non-sterile) and USP 797 (sterile) standards. The FDA does not pre-review compounded medications. Compounded GLP-1 formulations are dispensed cash-pay under personalized prescriptions when a licensed prescriber determines a personalized formulation is clinically appropriate.
Telehealth platforms connect patients with licensed prescribers via video or asynchronous messaging. Some route prescriptions to brand-name pharmacies, others to compounding pharmacies, some offer both. The quality range is enormous. Reasonable criteria for evaluating any platform: prescriber licensure in your state, a documented intake capturing medical history and contraindications, clear pricing, transparent pharmacy sourcing, and an accessible follow-up channel.
Traditional clinics and weight-management centers offer GLP-1 prescribing within a broader clinical workflow (nutrition counseling, body-composition measurement, integrated lab work). More friction, longer scheduling. But for patients with complex medical histories, multiple comorbidities, or endocrine concerns like HRT interactions, the in-person workflow is often worth it, at least at intake.
Reading the Trial Data Without Getting Fooled
Trial averages compress an enormous amount of variance into a single number. That's true for CombiPatch trials. It's equally true for GLP-1 trials.
SURMOUNT-1, for example, reported substantial differences in response within the same tirzepatide dose arm. Some participants lost significantly more weight than the mean; others lost significantly less. That's the normal pattern across the GLP-1 trials, and it's the normal pattern in HRT weight-change data too.
Real-world cohorts add even more variance, mostly from adherence and lifestyle differences. The right mental model treats any trial number as a useful anchor, not a guaranteed destination.
Across the GLP-1 class, the strongest single predictor of long-term outcome is months on therapy at or near the maintenance dose. Everything else, diet tweaks, exercise programs, supplement stacks, matters less than simply staying on the medication long enough for it to work.
Related reading in this cluster
The Four Lifestyle Inputs People Keep Underrating
Every published GLP-1 weight-loss trial included a lifestyle component. SURMOUNT-1, STEP 1, and the SURPASS series all included calorie guidance and physical-activity recommendations alongside the pharmacotherapy. The published results reflect the combined effect of medication plus lifestyle. Not medication alone.
This is like expecting a garden to thrive on rain but never sunlight. The medication is one input. It is a powerful input. It is not the whole system.
Four factors are consistently underweighted by patients:
Protein intake. Most women on combined HRT are not eating enough protein to preserve lean mass during weight loss. Aim for 0.7 to 1.0 grams per pound of lean body mass.
Resistance training. Cardio gets all the attention. Resistance training preserves muscle during pharmacologic weight loss, which matters both for metabolic rate and for long-term joint health.
Sleep quality. Poor sleep independently worsens insulin sensitivity and increases appetite-stimulating hormones. If you're on HRT for hot flashes and night sweats that wreck your sleep, and the patch is actually helping you sleep better, that metabolic benefit may partially offset any weight-gain tendency from the progestin.
Hydration. Boring but real. Adequate hydration reduces fluid-retention signals and supports the GI tolerance of GLP-1 medications.
Each one is a small lift to implement. Combined, they're a substantial multiplier on outcomes over months.
Related reading from adjacent topics
Regulatory Lines and What Changes Year to Year
The regulatory framework distinguishes between FDA-approved drugs (brand-name products) and compounded medications (prepared by state-licensed pharmacies under personalized prescriptions). The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Patient-specific compounding, not batch production for general inventory, is the legal foundation of the compounded GLP-1 model.
This space moves faster than most patients expect. Coverage decisions, manufacturer supply, FDA shortage status, and regulatory guidance all shift year to year. The right information this month may be out of date next month. Confirm specifics with your prescriber and pharmacy at every fill.
Recent trends include broadening insurance coverage for obesity-indicated GLP-1 medications, evolving cardiovascular-outcome evidence (SELECT for semaglutide), and ongoing investigation of obesity indications for additional incretin-targeted agents.
How to Evaluate Any Provider in This Space
Whether you're seeing a telehealth prescriber, an endocrinologist, or a weight-management clinic, the same handful of questions apply: Who prescribes? Where is the prescriber licensed? Where is the medication dispensed? What does the intake look like? How does follow-up work between visits? What's the pricing structure including refills? What's the policy on dose adjustments?
The answers should be clear, written, and verifiable. If any of them require digging or feel evasive, that is signal in its own right. I'd go so far as to say: opacity about pharmacy sourcing is the single biggest red flag in the compounded GLP-1 market right now.
Frequently Asked Questions
Does the CombiPatch cause weight gain in everyone?
No. Clinical trial data shows weight gain as a reported side effect in a subset of users, not a universal outcome. The progestin component (norethindrone acetate) is more commonly associated with fluid retention and appetite changes. Many women use the CombiPatch without meaningful weight change.
Should I discuss weight concerns with my prescriber?
Yes. Any question that affects how a prescription medication is dosed, stored, or administered is worth raising. This article provides general education, not a substitute for individualized clinical guidance.
Can I use a GLP-1 medication while on HRT?
Potentially. There is no absolute contraindication, but the combination should be managed by a prescriber who understands both treatments. Hormone status, metabolic labs, and body-composition goals all factor into the decision.
How often will the guidance here change?
The underlying mechanisms and foundational trial data are stable. Coverage, pricing, and regulatory specifics shift more often. Confirm anything time-sensitive with a current source.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
What if my situation is more complicated than the article describes?
Articles describe the general case. Complicated cases benefit from a longer prescriber visit, sometimes with additional specialty input. When something feels unusual, ask for the longer visit.
Continue the Series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About This Article
Written by Daniel Park, MS (Health Content Specialist). Medically reviewed by Dr. Hassan Karimi, MD (Board-Certified Endocrinology). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.